Carver Kyle — SEC insider filings
SEC reporting owner CIK 1757072. 9 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2021-01-12 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,000 shares, $13,260 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 18,175 shares, $415,117 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 18,175 shares @ $22.84 ($415,117) in Evommune, Inc., filed 2026-06-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Evommune, Inc. (EVMN) | Chief Financial Officer | 7 | 1 leg · 1,000 sh · $13,260 | 1 leg · 18,175 sh · $415,117 | 11 |
| Kadmon Holdings, Inc. (KDMN) | SVP, CAO, Controller | 2 | — | — | 7 |
Insider filings — Carver Kyle
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Evommune, Inc. (EVMN) | Disposition to issuer (D): 279,408 (derivative) · Grant/award (A): 279,408 (derivative) · Disposition to issuer (D): 98,946 (derivative) · Grant/award (A): 98,946 (derivative) | EDGAR |
| 2026-07-10 | 4 | Evommune, Inc. (EVMN) | Purchase (P): 1,000 @ $13.26 | EDGAR |
| 2026-06-01 | 4 | Evommune, Inc. (EVMN) | Option exercise (M): 15,000 @ $2.99 · Sale (S): 18,175 @ $22.84 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Evommune, Inc. (EVMN) | Grant/award (A): 98,946 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | Evommune, Inc. (EVMN) | Tax withholding (F): 13,290 @ $17.84 | EDGAR |
| 2025-11-12 | 4 | Evommune, Inc. (EVMN) | Conversion (C): 3,175 · Conversion (C): 25,000 (derivative) | EDGAR |
| 2025-11-07 | 4 | Evommune, Inc. (EVMN) | Grant/award (A): 279,408 (derivative) @ $0 | EDGAR |
| 2021-11-09 | 4 | Kadmon Holdings, Inc. (KDMN) | Disposition to issuer (D): 15,420 @ $9.50 · Disposition to issuer (D): 45,000 (derivative) @ $4.84 · Disposition to issuer (D): 55,000 (derivative) @ $5.86 · Disposition to issuer (D): 50,000 (derivative) @ $7.03 · Disposition to issuer (D): 100,000 (derivative) @ $5.16 · Disposition to issuer (D): 175,000 (derivative) @ $5.54 | EDGAR |
| 2021-01-12 | 4 | Kadmon Holdings, Inc. (KDMN) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1757072 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs